Transmedics Group

TMDX · NASDAQ

$74.75+$3.15 (+4.40%)TodayMarket closed ·
Prev close $71.60

About TMDX

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Employees
898
Headquarters
Andover, Massachusetts
Listed
May 2, 2019
Sector
Health Care
Industry
Health Care Equipment & Supplies

Leadership

Transmedics Group executives
NameTitleSince
James Tobin——
Waleed Hassanein—1998
Gerardo Hernandez——
Anil Ranganath——
Nicholas Corcoran——
Tamer Khayal——
Edward Basile——
Thomas Gunderson——
Edwin Kania——
Stephanie Lovell——
Merilee Raines——
David Weill——

Revenue by product and region

Fiscal year ended Dec 31, 2025: $605.49M total revenue

By product

  • Net product revenue [Member]$372.40M61.5%
  • Service Revenue [Member]$233.09M38.5%

By region

  • United States [Member]$584.70M96.6%
  • All Other Countries [Member]$16.70M2.8%

Similar companies

Companies in the same industry as Transmedics Group

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.